Biodistribution of intravenously administered amphiphilic β-cyclodextrin nanospheres

被引:29
作者
Geze, A.
Chau, L. Tieu
Choisnard, L.
Mathieu, J.-P.
Marti-Batlle, D.
Riou, L.
Putaux, J.-L.
Wouessidjewe, D.
机构
[1] Univ Grenoble 1, UFR Pharm, ICMG FR 2607, DPM UMR UJF CNRS 5063, F-38041 Grenoble 9, France
[2] Fac Med Grenoble 1, INSERM, E Radiopharmaceut Bioclin 0340, F-38700 La Tronche, France
[3] Univ Grenoble 1, Ctr Rech Macromol Vegetales CERMAV CNRS, F-38041 Grenoble 9, France
关键词
amphiphilic beta-cyclodextrin; nanosphere suspension; cryo-TEM; radiolabeling; gamma-scintigraphy; in vivo tissue distribution;
D O I
10.1016/j.ijpharm.2007.06.050
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Amphiphilic beta-cyclodextrin (beta CDa) nanospheres (mean diameter 90-110 nm) prepared by the solvent displacement method were developed as a colloidal drug delivery system. In order to survey the fate of these nanoparticles, the amphiphilic beta-cyclodextrin was first iodinated by a two-step procedure involving iodination of the primary face followed by an acylation of the secondary face. After radiolabeling of this derivative with I-125, nanospheres made of beta CDa/beta CDa I-125 Were formulated. After a single intravenous injection of labeled nanoparticles in mice, the organ distribution was analyzed from 10 min to 6 days. A rapid clearance of I-125-labeled beta CDa nanospheres from the blood circulation to the mononuclear phagocyte system was visualized by non-invasive planar imaging study. Radioactivity measurements in organs showed that the nanospheres mainly concentrated in the liver and the spleen where 28 and 24% of the radioactivity per gram of organ was, respectively, found 10 min after injection. At the opposite, the blood activity was low at that time and become negligible thereafter. Finally, the fact that no particular sign of toxicity is observed in injected animals should be emphasized since it is the first report on intravenous administration of beta CDa nanoparticles. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 36 条
[1]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[2]  
[Anonymous], [No title captured], Patent No. 5118528
[3]   Amino acid derivatives of beta-cyclodextrin [J].
Ashton, PR ;
Koniger, R ;
Stoddart, JF ;
Alker, D ;
Harding, VD .
JOURNAL OF ORGANIC CHEMISTRY, 1996, 61 (03) :903-908
[4]   Micellization of hydrophobically modified cyclodextrins.: 1.: Micellar structure [J].
Auzély-Velty, R ;
Djedaïni-Pilard, F ;
Désert, S ;
Perly, B ;
Zemb, T .
LANGMUIR, 2000, 16 (08) :3727-3734
[5]  
Barratt, 2000, Pharm Sci Technol Today, V3, P163
[6]   STEALTH ME.PEG-PLA NANOPARTICLES AVOID UPTAKE BY THE MONONUCLEAR PHAGOCYTES SYSTEM [J].
BAZILE, D ;
PRUDHOMME, C ;
BASSOULLET, MT ;
MARLARD, M ;
SPENLEHAUER, G ;
VEILLARD, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (04) :493-498
[7]   Enzymatic production of cyclodextrins [J].
Biwer, A ;
Antranikian, G ;
Heinzle, E .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2002, 59 (06) :609-617
[8]   Nanoparticles of β-cyclodextrin esters obtained by self-assembling of biotransesterified β-cyclodextrins [J].
Choisnard, L ;
Gèze, A ;
Putaux, JL ;
Wong, YS ;
Wouessidjewe, D .
BIOMACROMOLECULES, 2006, 7 (02) :515-520
[9]  
Choisnard L, 2005, J PHARM PHARM SCI, V8, P593
[10]   Nanotechnology: Intelligent design to treat complex disease [J].
Couvreur, Patrick ;
Vauthier, Christine .
PHARMACEUTICAL RESEARCH, 2006, 23 (07) :1417-1450